DK0659410T3 - Anvendelse af det aktive middel flupirtin til fremstilling af et lægemiddel til bekæmpelse af muskelspændinger - Google Patents

Anvendelse af det aktive middel flupirtin til fremstilling af et lægemiddel til bekæmpelse af muskelspændinger

Info

Publication number
DK0659410T3
DK0659410T3 DK95101189T DK95101189T DK0659410T3 DK 0659410 T3 DK0659410 T3 DK 0659410T3 DK 95101189 T DK95101189 T DK 95101189T DK 95101189 T DK95101189 T DK 95101189T DK 0659410 T3 DK0659410 T3 DK 0659410T3
Authority
DK
Denmark
Prior art keywords
flupirtine
drug
manufacture
active agent
muscle tension
Prior art date
Application number
DK95101189T
Other languages
Danish (da)
English (en)
Inventor
Ralph Dr Venhaus
Juergen Prof Engel
Bernd Dr Nickel
Michael Dr Lobisch
Peter Dr Emig
Istvan Prof Szelenyi
Original Assignee
Awd Pharma Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Awd Pharma Gmbh & Co Kg filed Critical Awd Pharma Gmbh & Co Kg
Application granted granted Critical
Publication of DK0659410T3 publication Critical patent/DK0659410T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Golf Clubs (AREA)
  • Details Of Television Scanning (AREA)
  • Paints Or Removers (AREA)
DK95101189T 1990-07-14 1991-07-04 Anvendelse af det aktive middel flupirtin til fremstilling af et lægemiddel til bekæmpelse af muskelspændinger DK0659410T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4022442 1990-07-14
IN421CA1991 IN172468B (OSRAM) 1990-07-14 1991-06-04

Publications (1)

Publication Number Publication Date
DK0659410T3 true DK0659410T3 (da) 2001-12-27

Family

ID=25895002

Family Applications (2)

Application Number Title Priority Date Filing Date
DK95101189T DK0659410T3 (da) 1990-07-14 1991-07-04 Anvendelse af det aktive middel flupirtin til fremstilling af et lægemiddel til bekæmpelse af muskelspændinger
DK91111124.3T DK0467164T3 (da) 1990-07-14 1991-07-04 Anvendelse af det virksomme stof flupirtin i kombination med antiparkinsonika til bekæmpelse af muskelspændinger

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK91111124.3T DK0467164T3 (da) 1990-07-14 1991-07-04 Anvendelse af det virksomme stof flupirtin i kombination med antiparkinsonika til bekæmpelse af muskelspændinger

Country Status (30)

Country Link
US (2) US5162346A (OSRAM)
EP (2) EP0659410B1 (OSRAM)
KR (1) KR0182811B1 (OSRAM)
CN (1) CN1070700C (OSRAM)
AT (2) ATE133564T1 (OSRAM)
AU (1) AU634073B2 (OSRAM)
CA (1) CA2046943C (OSRAM)
CZ (1) CZ280879B6 (OSRAM)
DE (3) DE4122166A1 (OSRAM)
DK (2) DK0659410T3 (OSRAM)
EG (1) EG19814A (OSRAM)
ES (2) ES2082887T3 (OSRAM)
GR (1) GR3019179T3 (OSRAM)
HR (1) HRP920667B1 (OSRAM)
HU (1) HU206973B (OSRAM)
IE (1) IE74688B1 (OSRAM)
IL (1) IL98810A (OSRAM)
IN (1) IN172468B (OSRAM)
LT (1) LT3593B (OSRAM)
LV (1) LV10048B (OSRAM)
MC (1) MC2272A1 (OSRAM)
MX (1) MX9100160A (OSRAM)
NO (1) NO912758L (OSRAM)
NZ (1) NZ238940A (OSRAM)
PT (1) PT98291B (OSRAM)
RO (1) RO108220B1 (OSRAM)
RU (1) RU2070408C1 (OSRAM)
SI (1) SI9111227B (OSRAM)
SK (1) SK279567B6 (OSRAM)
ZA (1) ZA915466B (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9321574U1 (de) * 1992-03-11 2000-06-29 Asta Medica Ag, 01277 Dresden Tabletten, Granulate und Pellets mit hohem Gehalt an Wirkstoffen für hochkonzentrierte, feste Darreichungsformen
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
GB9426079D0 (en) * 1994-12-23 1995-02-22 Orion Yhtymae Oy A gelatine capsule
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
HUP0301296A2 (hu) * 1999-08-03 2003-08-28 Awd.Pharma Gmbh & Co. Kg Flupirtin alkalmazása degeneratív ízületi fájdalom kezelésére
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
RU2213565C1 (ru) * 2002-06-24 2003-10-10 Общество с ограниченной ответственностью "Паркинфарм" Способ лечебного воздействия на организм пациента при лечении болезни паркинсона
DE10255415A1 (de) * 2002-11-28 2004-06-09 Bayer Healthcare Ag Dermale Applikation von Flupirtin
DE10327674A1 (de) * 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
WO2005072705A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
US20050220862A1 (en) 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
EP1874282B1 (en) 2005-04-06 2010-09-15 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
WO2007128462A1 (en) * 2006-05-02 2007-11-15 Chris Rundfeldt Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
CA2661462C (en) * 2006-08-23 2015-09-29 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
JP2010511052A (ja) * 2006-11-28 2010-04-08 バレアント ファーマシューティカルズ インターナショナル カリウムチャネル調節因子としての１，４ジアミノ二環式レチガビンアナログ
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
NZ582942A (en) * 2007-08-01 2011-09-30 Lundbeck & Co As H Use of kncq potassium channel openers for treating attention deficit hyperactivity disorder (adhd) or aggression
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
ES2347119B2 (es) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela Nanocapsulas de poliarginina.
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
JP6251667B2 (ja) * 2014-06-03 2017-12-20 アサヒカルピスウェルネス株式会社 錠剤型即放性製剤及びその製造方法
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
NZ787838A (en) 2019-11-08 2025-08-29 Xenon Pharmaceuticals Inc Methods of treating depressive disorders
MX2023009314A (es) 2021-02-09 2023-08-16 Xenon Pharmaceuticals Inc Apertura del canal de potasio dependiente de voltaje para usarse en el tratamiento de la anhedonia.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1795858C2 (de) 1968-07-19 1979-01-11 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Benzylaminopyridine
DE3133519A1 (de) 1980-09-13 1982-06-09 Degussa Ag, 6000 Frankfurt "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat"
EP0189788B1 (de) * 1985-01-23 1989-09-13 ASTA Pharma Aktiengesellschaft Synergistische Kombination von Flupirtin und nicht-steroidalen Antiphlogistika
DE3663775D1 (en) * 1985-02-23 1989-07-13 Asta Pharma Ag Combination of flupirtin with spasmolytics having an anticholinergic effect
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
FI855016A7 (fi) * 1985-06-28 1986-12-29 Degussa Flupirtiinin ja 4-asetamido-fenolin synergistinen yhdistelmä.

Also Published As

Publication number Publication date
AU8040391A (en) 1992-01-16
HU206973B (en) 1993-03-01
EP0467164B1 (de) 1996-01-31
NO912758D0 (no) 1991-07-12
MC2272A1 (fr) 1993-06-23
EP0467164A3 (en) 1992-04-15
ZA915466B (en) 1992-04-29
LV10048A (lv) 1994-05-10
CA2046943C (en) 1996-03-12
DE4122166A1 (de) 1992-01-16
HRP920667B1 (en) 1998-06-30
IL98810A (en) 1996-01-19
KR920002147A (ko) 1992-02-28
CA2046943A1 (en) 1992-01-15
ES2082887T3 (es) 1996-04-01
DE59107331D1 (de) 1996-03-14
EG19814A (en) 1996-02-29
PT98291B (pt) 1999-01-29
MX9100160A (es) 1992-02-28
HU912359D0 (en) 1991-12-30
DK0467164T3 (da) 1996-03-04
IN172468B (OSRAM) 1993-08-14
CS210191A3 (en) 1992-02-19
GR3019179T3 (en) 1996-06-30
CN1070700C (zh) 2001-09-12
EP0659410B1 (de) 2001-10-17
AU634073B2 (en) 1993-02-11
EP0659410A2 (de) 1995-06-28
RU2070408C1 (ru) 1996-12-20
DE59109222D1 (de) 2001-11-22
CZ280879B6 (cs) 1996-04-17
EP0659410A3 (de) 1995-10-25
SK279567B6 (sk) 1999-01-11
ATE206919T1 (de) 2001-11-15
RO108220B1 (ro) 1994-03-31
PT98291A (pt) 1992-05-29
LT3593B (en) 1995-12-27
SI9111227B (sl) 2000-12-31
HUT59313A (en) 1992-05-28
IL98810A0 (en) 1992-07-15
ATE133564T1 (de) 1996-02-15
KR0182811B1 (ko) 1999-05-01
NO912758L (no) 1992-01-15
SI9111227A (en) 1995-06-30
LTIP919A (en) 1995-03-27
IE912451A1 (en) 1992-01-15
ES2164111T3 (es) 2002-02-16
CN1058716A (zh) 1992-02-19
US5284861A (en) 1994-02-08
HRP920667A2 (en) 1996-10-31
IE74688B1 (en) 1997-07-30
NZ238940A (en) 1997-05-26
US5162346A (en) 1992-11-10
EP0467164A2 (de) 1992-01-22
LV10048B (en) 1995-06-20

Similar Documents

Publication Publication Date Title
DK0659410T3 (da) Anvendelse af det aktive middel flupirtin til fremstilling af et lægemiddel til bekæmpelse af muskelspændinger
DK1039887T3 (da) Anvendelse af aminothiolforbindelser til behandling af neuro- og nefrolidelser og terapeutiske toksiciteter
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
ATE169219T1 (de) Behandlung von katarakt mit 15-keto- prostaglandinderivaten
DK0687176T3 (da) Anvendelse af riluzol til behandling af AIDS-relaterede nervesygdomme
DK0501705T3 (da) Anvendelse af tomoxetin til behandling af sygdomme i de nedre urinveje
YU49215B (sh) Primena flupirtina za dobijanje medikamenta za tretman neurodegenerativnih oboljenja
ATE174221T1 (de) Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
DK0467564T3 (da) Behandling af inflammatoriske sygdomme med 15-ketoprostaglandinforbindelser
PT783495E (pt) Derivados de quinoxalina uteis em terapia
DK0617959T3 (da) Lægemiddel til behandling af hudsygdomme
DK671087D0 (da) Anvendelse af 5-aryl-3h-1,2,4-triazol-3-oner som antikonvulsiva
DK0454429T3 (da) Anvendelse af 15-dehydroxy-16-oxoprostaglandinderivater til behandling af allergiske sygdomme
DK0547223T3 (da) Middel mod hornhindelidelser
ATE146964T1 (de) Behandlung von katarakt mit prostacyclinverbindungen
SE8703308D0 (sv) Therapeutic agent for the treatment of disorders associated with cerebral ischemia
DK0429324T3 (da) Anvendelse af N-methyl-2-(3pyridyl)-tetrahydrothiopyran-2-carbothioamid-1-oxid til fremstilling af lægemidler beregnet til behandling af coronarinsufficiens
KR970020846U (ko) 근골격계질환 치료보조용 반창고